The European Association for the Study of the Liver (EASL) Congress was held in Milan, Italy on 5-8 June 2024. Check out the official website of the Congress.
Here is selected coverage on viral hepatitis:
Hepatitis B:
- Aligos Therapeutics presents positive data at the EASL Congress 2024 /press release/
- Arbutus’ imdusiran with short course interferon achieves sustained undetectable HBsAg, a necessity for HBV functional cure /press release/
- Barinthus Bio’s VTP-300 trials demonstrate ability to achieve undetectable HBsAg levels and statistical significance in lowering HBsAg levels in people with chronic hepatitis B /press release/
- Treatment with Arbutus’ imdusiran and VTP-300 achieves statistical significance in lowering HBsAg levels /press release/
- Virion Therapeutics reports positive first-in-human, first-in-class, Phase 1b immunogenicity data of VRON-0200, a novel checkpoint modifier for HBV functional cure at EASL Congress /press release/
- Precision BioSciences presents new preclinical safety data for PBGENE-HBV clinical candidate at EASL Congress /press release/
- Brii Bio presents new data from its ongoing Phase 2 chronic hepatitis B trials at EASL™ Congress 2024 /press release/
Hepatitis D:
- Assembly Biosciences presents new data highlighting hepatitis D virus entry inhibitor ABI-6250 at the EASL Congress™ 2024 /press release/
- Tobevibart monotherapy and combination therapy with elebsiran achieved high virologic response and ALT normalization in people living with the hepatitis delta virus after 12 and 24 weeks of treatment /press release/
- Gilead announces New England Journal of Medicine publication of data that demonstrate bulevirtide with PegIFN achieved post-treatment undetectable HDV RNA /press release/
— SEE ALSO: Healio: VIDEO: Bulevirtide plus PEG-IFN a-2a potentially ‘viable finite therapy’ for chronic HDV
— SEE ALSO: MedPage Today: Bulevirtide/pegylated interferon combo beats monotherapy for chronic hepatitis D
- Bluejay Therapeutics presents positive preliminary BJT-778 data from Phase 2 clinical trial in chronic hepatitis D at EASL 2024 Congress /press release/
Hepatitis C:
— SEE ALSO: Contagion Live: Investigational HCV therapy shows a 97% sustained virologic response rate
Related HIV and Co-Infections News
-
HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure
-
Highlights from The Liver Meeting 2024
-
Vir Biotechnology receives positive opinion on orphan drug designation for tobevibart and elebsiran in chronic hepatitis delta from EMA
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.
